Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AllerT pre-seasonal treatment in adults with birch pollen allergy
2011-002259-32Phase 2Completed
- Sponsor
- Anergis
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cetirizine in birch pollen allergy and allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by Anergis. Primary endpoint: Average combined Rhinoconjunctivitis Symptom and Medication Score during birch pollen season. Started Jun 2012; status: completed.
02
Drugs
cetirizine
03
Conditions
birch pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2011-002259-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002259-32.